QPPV.COM

Drug-Induced Cardiac Toxicity: Cardiovascular Safety Assessment in Clinical Development and Pharmacovigilance

Understand how potential drug-induced cardiac toxicity is identified and medically evaluated, how ICH E14 and S7B support assessment of QT/QTc and proarrhythmic risk, and how cardiovascular safety signals are assessed across clinical development and pharmacovigilance.

Audio Lesson 12 min
Knowledge Assessment Test your understanding of this article. Take the assessment →

Drug-Induced Cardiac Toxicity: Cardiovascular Safety Assessment in Clinical Development and Pharmacovigilance

Introduction

The cardiovascular system is an important target of unintended drug effects. Medicinal products can alter cardiac electrophysiology, myocardial function, vascular tone, blood pressure, heart rate or coronary physiology. In some circumstances these effects may produce serious outcomes including ventricular arrhythmia, heart failure, myocardial infarction, stroke or sudden cardiac death.

Cardiovascular safety assessment is therefore broader than simply monitoring electrocardiograms.

A drug may produce a clinically important cardiovascular effect without prolonging the QT interval. Conversely, QT prolongation may occur without a clinically important arrhythmia. A rise in cardiac troponin may indicate myocardial injury without representing myocardial infarction. A reduction in left ventricular ejection fraction may indicate myocardial dysfunction without immediately producing symptomatic heart failure.

The central challenge is therefore to determine what cardiovascular change occurred, whether it is clinically meaningful, and whether the medicinal product is the most plausible explanation.

This requires integration of:

ICH E14 addresses clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH S7B addresses nonclinical evaluation of delayed ventricular repolarization. FDA's 2022 E14/S7B Questions and Answers further describe how clinical and nonclinical information can be integrated into an overall proarrhythmic risk assessment. [1][2][3]

The distinction between these frameworks and broader cardiovascular safety assessment is important.

There is no single laboratory threshold or single algorithm that defines drug-induced cardiac toxicity.

Instead, cardiovascular safety assessment uses several complementary approaches depending on the suspected mechanism and clinical context. [9]

For pharmacovigilance professionals, the objective is not simply to identify an adverse event coded as "cardiac."

The objective is to understand the cardiovascular phenotype.

Learning Objectives

After reading this article, the reader should be able to:

Understanding Drug-Induced Cardiac Toxicity

What Is Drug-Induced Cardiac Toxicity?

Drug-induced cardiac toxicity refers to an adverse effect of a medicinal product on cardiac structure, function, electrophysiology or cardiovascular physiology.

The term is broad.

Potential manifestations include:

The mechanism may be:

The same medicinal product may produce more than one cardiovascular phenotype.

For example, a drug may reduce heart rate through autonomic effects while also affecting ventricular repolarization. Another drug may produce hypertension that increases cardiovascular risk over prolonged exposure without producing an acute cardiac event.

Cardiac safety assessment must therefore be mechanism-aware.

Why the Cardiovascular System Is Vulnerable

The cardiovascular system is continuously active.

Cardiac contraction, electrical conduction and vascular tone depend on tightly regulated ion channels, receptors, signaling pathways, calcium handling, myocardial metabolism and autonomic control.

Small pharmacological changes can therefore have substantial physiological consequences in susceptible individuals.

The cardiovascular system is also highly interconnected with other organ systems.

Renal dysfunction can alter electrolyte concentrations and drug exposure.

Liver dysfunction can alter drug metabolism.

Electrolyte abnormalities can increase arrhythmic susceptibility.

Hypoxia and anemia can increase myocardial oxygen demand or reduce oxygen delivery.

Drug interactions can increase concentrations of a compound that affects cardiac repolarization.

Therefore, cardiovascular safety cannot always be assessed independently of the rest of the patient.

Major Phenotypes of Cardiovascular Toxicity

Electrophysiological Toxicity

Electrophysiological toxicity includes effects on:

QT/QTc prolongation is one of the most extensively studied drug-induced electrophysiological effects because excessive ventricular repolarization delay can increase the risk of torsades de pointes.

However, QT prolongation is only one component of electrophysiological safety.

Myocardial Injury

Myocardial injury refers to damage or injury to cardiac myocytes.

Cardiac troponins are important biomarkers because they are sensitive indicators of myocardial injury.

An elevated troponin concentration does not by itself establish myocardial infarction.

Troponin may increase in conditions including:

Consequently, troponin must be interpreted with symptoms, ECG findings, imaging and clinical context.

FDA has evaluated cardiac troponins as biomarkers of cardiac injury, including their potential application in drug-development safety assessment. [4]

Myocardial Dysfunction and Heart Failure

Some medicinal products can impair myocardial contractility or otherwise produce ventricular dysfunction.

Relevant findings may include:

A reduction in ejection fraction does not automatically mean symptomatic heart failure.

Conversely, clinically important heart failure may occur without a dramatic single measurement of ejection fraction.

Medical review therefore needs to integrate structural, functional and clinical information.

Vascular and Blood-Pressure Effects

Drugs may alter:

Hypertension can be clinically important because sustained blood-pressure elevation increases cardiovascular risk.

Hypotension may produce:

FDA has specifically addressed the assessment of pressor effects during drug development. [5]

QT/QTc Prolongation

What Is the QT Interval?

The QT interval on an ECG represents the period from the beginning of ventricular depolarization through ventricular repolarization.

The duration varies with heart rate.

At faster heart rates, the QT interval generally becomes shorter.

At slower heart rates, it generally becomes longer.

For this reason, QT is usually corrected for heart rate to produce a QTc value.

Why QT Correction Matters

Comparing raw QT intervals across patients or across time can be misleading when heart rate differs.

QT correction attempts to reduce the effect of heart rate so that changes in ventricular repolarization can be assessed more consistently.

Common correction methods include:

No correction method is perfect across all heart rates.

This is why the choice of correction method should be prespecified and interpreted in the context of the study design. [8]

QTc Is Not the Same as Torsades de Pointes

This distinction is fundamental.

QTc prolongation is a measurable electrophysiological effect.

Torsades de pointes is a ventricular tachyarrhythmia.

The relationship is probabilistic rather than deterministic.

A drug that prolongs QTc does not necessarily cause torsades de pointes.

Conversely, clinically important proarrhythmic risk may involve mechanisms that are not fully captured by QTc alone.

The modern regulatory approach therefore increasingly emphasises integrated proarrhythmic risk assessment rather than treating one QTc threshold as an automatic prediction of clinical events. [3]

ICH E14 and S7B

The Regulatory Framework

ICH E14 addresses clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential.

ICH S7B addresses nonclinical evaluation of the potential for delayed ventricular repolarization.

Together they provide complementary clinical and nonclinical components of cardiac repolarization risk assessment.

FDA's E14 guidance describes assessment of QT/QTc effects and collection of cardiovascular adverse events, with the approach tailored to the pharmacological, pharmacokinetic and safety characteristics of the product. [1]

S7B describes a nonclinical testing strategy including assays and integrated assessment of delayed ventricular repolarization. [2] S7A provides the broader safety-pharmacology framework within which cardiovascular safety pharmacology is considered. [9]

Why E14 and S7B Should Be Considered Together

Historically, drug development placed substantial emphasis on:

The modern framework is more integrated.

Nonclinical data can help explain mechanisms and identify potential risk.

Clinical ECG data demonstrate what happens in humans. [8]

Pharmacokinetic data connect exposure to pharmacodynamic effects.

Clinical adverse events provide outcome information.

The result is a more comprehensive assessment of proarrhythmic potential. [9]

The 2022 E14/S7B Q&A specifically supports integration of these data streams. [3]

Concentration-QTc Analysis

Concentration-QTc analysis is an important pharmacometric approach.

Instead of considering QTc changes only according to nominal dose, the analysis examines the relationship between drug concentration and QTc.

This is valuable because two subjects receiving the same nominal dose may have different systemic exposure.

Exposure may differ because of:

A concentration-QTc relationship can therefore provide more informative evidence about whether the drug itself affects ventricular repolarization.

FDA recognises concentration-QT analysis as an accepted approach for assessing QT prolongation potential. [6]

Clinical ECG Assessment

Baseline ECG

Baseline ECG assessment provides context for subsequent findings.

The reviewer should consider:

A patient with a prolonged baseline QTc may have a different risk profile from a patient with a normal baseline ECG.

Change From Baseline

A QTc increase can be evaluated as:

The appropriate analysis depends upon the study design.

A single isolated post-dose value should not automatically be interpreted as evidence of a treatment-related effect.

Outliers

Large clinical datasets may contain individual QTc outliers.

An outlier should trigger appropriate review rather than automatic attribution.

The reviewer should consider:

Automated identification is useful for screening, but medical interpretation remains necessary.

Risk Factors for Drug-Induced Proarrhythmia

Important risk factors may include:

The presence of risk factors does not prove that a drug caused an event.

It changes the biological plausibility and the background susceptibility.

Drug characteristics may include:

The reviewer should therefore examine both pharmacology and observed clinical data.

Electrolytes

Electrolytes are particularly important in the assessment of arrhythmic risk.

Relevant abnormalities may include:

A patient with QT prolongation and significant electrolyte abnormalities may have a different causal interpretation from a patient with normal electrolytes.

Electrolyte disturbances can also act as confounders when evaluating treatment-emergent QT changes.

Arrhythmias

Ventricular Arrhythmias

Potential drug-related ventricular events include:

The clinical significance depends on:

A non-sustained ventricular tachycardia episode and ventricular fibrillation are both ventricular arrhythmias but have profoundly different clinical implications.

Atrial Arrhythmias

Drugs may also contribute to:

Assessment should consider:

Atrial arrhythmias are common in the general population, making background incidence particularly important.

Bradycardia and Tachycardia

Changes in heart rate may be:

A change in heart rate should therefore not automatically be classified as cardiac toxicity.

The clinical context determines significance.

Myocardial Injury and Cardiac Troponin

What Is Cardiac Troponin?

Cardiac troponin I and troponin T are biomarkers of myocardial injury.

Modern high-sensitivity assays can detect small concentrations of circulating troponin.

This sensitivity is clinically valuable but creates an important interpretive challenge:

a detectable or elevated troponin concentration is not synonymous with myocardial infarction.

Troponin indicates myocardial injury.

The cause of that injury requires clinical evaluation.

Troponin in Drug Development

Troponin may be particularly useful when there is a mechanistic reason to suspect myocardial injury.

Potential scenarios include:

However, routine measurement of troponin in every clinical-development programme is not automatically necessary.

Its use should be driven by:

FDA has noted that the application of cardiac troponins to non-acute-coronary-syndrome drug-development settings requires appropriate interpretation and remains context dependent. [4]

Troponin Versus Myocardial Infarction

Myocardial infarction is a clinical diagnosis involving myocardial injury in an ischemic context.

A troponin rise alone is insufficient to establish myocardial infarction.

The reviewer should consider:

This distinction is especially important in pharmacovigilance because a case coded as "troponin increased" may represent a very different clinical situation from an adjudicated myocardial infarction.

Heart Failure and Left Ventricular Dysfunction

Left Ventricular Ejection Fraction

Left ventricular ejection fraction is commonly used to assess systolic function.

A decline may indicate myocardial dysfunction.

However, ejection fraction is affected by:

A small numerical change should therefore not automatically be interpreted as clinically meaningful cardiotoxicity.

Natriuretic Peptides

BNP and NT-proBNP can provide information about myocardial wall stress.

They may support evaluation of suspected heart failure.

However, concentrations can be affected by:

As with troponin, they are not disease-specific in isolation.

Clinical Heart Failure

Potential symptoms include:

Potential clinical findings include:

The medical reviewer should integrate symptoms, signs, imaging and biomarkers.

Myocarditis

Drug-Induced Myocarditis

Some medicines, particularly certain immune-modulating therapies, may be associated with myocarditis.

Potential findings include:

The diagnosis requires clinical integration and may involve:

A troponin increase alone should not automatically be labelled myocarditis.

Why Myocarditis Requires Rapid Recognition

Myocarditis can progress rapidly in some patients.

A safety physician should therefore pay particular attention to combinations of:

The seriousness of the clinical syndrome may be more informative than any single laboratory threshold.

Blood Pressure and Vascular Safety

Hypertension

Drug-induced hypertension can be:

Persistent blood-pressure elevation can increase cardiovascular risk.

FDA has issued guidance concerning premarketing assessment of pressor effects of drugs. [5]

Hypotension

Hypotension may be associated with:

A low blood-pressure reading must therefore be interpreted clinically.

A single asymptomatic reading is different from persistent hypotension associated with syncope or shock.

Cardiovascular Safety in Clinical Development

Individual-Subject Review

Individual medical review may be required for subjects with:

The reviewer should reconstruct the clinical sequence rather than reviewing isolated data points.

Population-Level Review

At the population level, teams may examine:

The purpose is to determine whether a consistent treatment-related pattern exists.

Treatment Versus Control

Cardiovascular events are often common background events.

This makes the control group particularly important.

The reviewer should consider:

An apparent imbalance becomes more informative when it is biologically plausible and consistent across related endpoints.

Exposure-Response

Exposure-response relationships can strengthen causal interpretation.

For example, increasing QTc effect with increasing drug concentration provides evidence that the observed electrophysiological change may be pharmacologically mediated.

Similarly, exposure-related changes in blood pressure or heart rate may support a pharmacodynamic mechanism.

However:

exposure-response association does not by itself establish clinical harm.

The magnitude, reversibility, clinical consequences and mechanism remain important.

Integrated Proarrhythmic Risk Assessment

Why QTc Alone Is Insufficient

A QTc change is one piece of evidence.

The overall proarrhythmic assessment may integrate:

The purpose is to determine the likelihood that the drug creates clinically meaningful proarrhythmic risk.

The E14/S7B framework is specifically designed around this integrated approach. [3]

The Role of Nonclinical Data

Nonclinical studies can examine:

S7B provides a framework for nonclinical evaluation of delayed ventricular repolarization. [2]

Nonclinical findings should be interpreted alongside human clinical data rather than treated as independent proof of clinical risk.

The Role of Pharmacokinetics

Exposure is central to cardiac safety interpretation.

A small QT effect at very low therapeutic exposure may have a different significance from the same effect occurring only at concentrations substantially above the expected clinical range.

The reviewer should consider:

Post-Marketing Pharmacovigilance

Sources of Cardiovascular Safety Information

Post-marketing cardiovascular information may arise from:

Each source has different strengths and limitations.

Spontaneous reports can identify unexpected rare events but may contain incomplete clinical information.

Clinical studies may provide better denominator information but may involve selected populations.

Case-Level Medical Review

A potential cardiovascular case should be reconstructed chronologically.

The reviewer should establish:

The objective is to determine the most plausible clinical diagnosis before determining causality.

Signal Detection

Population-level pharmacovigilance may identify patterns involving:

Signal detection should then progress to clinical evaluation.

A statistical signal does not automatically establish causality. Population-level resources such as FDA's Drug-Induced Cardiotoxicity Rank (DICTrank) dataset can provide additional context when evaluating patterns of drug-associated cardiotoxicity. [10]

Aggregate Assessment

An aggregate assessment may consider:

FDA's pharmacovigilance guidance emphasises the need to identify and interpret safety signals using appropriate clinical and epidemiological approaches. [7]

Worked Examples

Example 1: QTc Increase Without Arrhythmia

A subject has:

Baseline QTc = 420 ms

Post-dose QTc = 455 ms

The subject has no symptoms, no arrhythmia and normal potassium and magnesium.

The finding warrants appropriate evaluation.

However, the reviewer should consider:

The finding does not establish torsades de pointes risk in the individual patient.

Example 2: QTc Prolongation With Electrolyte Abnormality

A subject develops:

QTc = 510 ms

Potassium = markedly reduced

The subject is receiving a medication known to affect potassium balance.

The QTc abnormality is clinically important, but attribution to the investigational drug requires consideration of the electrolyte disturbance and all concomitant exposures.

The appropriate conclusion may be that the subject has clinically significant QT prolongation with multiple potential contributors.

Example 3: Troponin Elevation

A subject develops a new increase in high-sensitivity cardiac troponin.

The patient has no chest pain.

ECG is unchanged.

The patient has severe renal impairment and an episode of sepsis.

The troponin result indicates myocardial injury but does not by itself establish myocardial infarction or drug-induced myocardial toxicity.

The reviewer must consider the complete clinical context.

Example 4: Left Ventricular Dysfunction

A subject has:

Baseline LVEF = 62%

Follow-up LVEF = 48%

The patient has no heart-failure symptoms.

A repeat echocardiogram confirms the finding.

The reviewer should assess:

A reduction in LVEF may represent clinically relevant myocardial dysfunction, but causality requires further assessment.

Example 5: Myocarditis Pattern

A subject receiving an immune-modulating medicine develops:

This combination is more concerning than any isolated finding.

The case requires urgent clinical assessment and consideration of myocarditis and other causes of myocardial injury.

The safety assessment should document the clinical reasoning, investigations, treatment and outcome.

Limitations of Cardiovascular Safety Assessment

No Single Cardiac Biomarker

There is no universal biomarker that identifies all forms of drug-induced cardiac toxicity.

Troponin reflects myocardial injury.

BNP and NT-proBNP provide information about myocardial wall stress.

QTc reflects ventricular repolarization.

Blood pressure reflects hemodynamic effects.

LVEF reflects one aspect of ventricular systolic function.

Each answers a different question.

QTc Has Measurement Limitations

QT measurement can be affected by:

A QTc value should therefore be interpreted in the context of how and when it was obtained.

Cardiovascular Events Have High Background Incidence

Many cardiovascular events occur commonly in the general population.

Examples include:

As a result, background risk can make causal attribution difficult.

Age, diabetes, hypertension, smoking, obesity, dyslipidemia and pre-existing cardiovascular disease can all influence event rates.

Multiple Mechanisms May Coexist

A drug may:

The resulting cardiovascular event may therefore have multiple contributing factors.

Causality assessment should not force a complex clinical event into a single mechanism when the evidence does not support that simplification.

Practical Medical Review Framework

Step-by-Step Cardiovascular Safety Review

A structured review may proceed through the following sequence:

  1. Confirm the cardiovascular event or abnormality.
  2. Establish the baseline cardiovascular status.
  3. Confirm ECG, laboratory and imaging data.
  4. Establish the treatment timeline.
  5. Determine the phenotype.
  6. Review exposure and pharmacokinetics.
  7. Review concomitant medications.
  8. Assess electrolytes and relevant laboratory values.
  9. Evaluate alternative cardiovascular and systemic causes.
  10. Assess symptoms and clinical severity.
  11. Review dechallenge.
  12. Review rechallenge where applicable.
  13. Assess whether the finding is biologically plausible for the product.
  14. Determine whether similar cases exist.
  15. Determine the most likely clinical diagnosis.
  16. Assess causality.
  17. Document the medical rationale.

This prevents a laboratory or ECG value from becoming a diagnosis by default.

Medical Documentation

A medically important cardiac safety case should document, as appropriate:

Another qualified reviewer should be able to reconstruct the reasoning from the available documentation.

Pharmacovigilance and Inspection Considerations

Inspection Perspective

During an inspection, an organisation should be able to demonstrate how clinically important cardiovascular signals were identified and evaluated.

An inspector may reasonably ask:

The organisation should therefore be able to demonstrate both the analytical process and the medical decision-making.

Common Documentation Weaknesses

Potential weaknesses include:

Good documentation should allow an independent reviewer to understand both the observed phenotype and the reasoning used to determine causality.

Common Mistakes in Cardiac Safety Assessment

Common errors include:

What an Experienced Safety Physician Looks For

An experienced safety physician does not begin with:

"Does this patient have a cardiac adverse event?"

The first question is:

"What cardiovascular phenotype is actually present?"

The reviewer then asks:

Only after these questions have been considered should the reviewer determine whether the medicinal product is a plausible cause.

Cardiac Safety Compared With Liver and Kidney Safety

The three organ systems illustrate an important principle in pharmacovigilance.

Organ system Important assessment framework
Liver Hy's Law, eDISH, liver-test pattern and causality assessment
Kidney AKI, creatinine/eGFR, urine findings, injury biomarkers and renal phenotype
Heart QT/QTc, E14/S7B, myocardial injury, ventricular function, arrhythmia and cardiovascular phenotype

The frameworks are different because the biology is different.

Liver safety has a relatively well-known population-level Hy's Law concept.

Kidney safety relies on multiple measures of function and injury.

Cardiac safety requires several complementary domains because electrophysiology, myocardial injury, contractility and vascular physiology are distinct processes.

This is why there is no single "cardiac Hy's Law."

Key Takeaways

Drug-induced cardiac toxicity encompasses a broad range of effects involving electrophysiology, myocardial injury, ventricular function, blood pressure, vascular physiology and clinical cardiovascular outcomes.

QT/QTc prolongation is an important component of cardiac safety assessment but should not be equated with torsades de pointes or sudden cardiac death.

ICH E14 and S7B provide complementary clinical and nonclinical frameworks for evaluating delayed ventricular repolarization and proarrhythmic potential. [1][2]

The modern approach emphasises integration of:

Cardiac troponin is an important marker of myocardial injury but does not by itself establish myocardial infarction or drug causality.

Similarly, a reduction in LVEF does not automatically establish drug-induced heart failure.

A robust cardiovascular safety assessment therefore integrates:

The most important principle is:

Cardiovascular safety assessment should identify what changed, establish the clinical phenotype, determine whether the change is meaningful, and assess whether the medicinal product is the most plausible cause.

References

  1. U.S. Food and Drug Administration. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Guidance for Industry. 2005.

  2. U.S. Food and Drug Administration. S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Guidance for Industry. 2005.

  3. U.S. Food and Drug Administration. E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential—Questions and Answers. Guidance for Industry. August 2022.

  4. U.S. Food and Drug Administration. Review of Qualification Data for Cardiac Troponins. Center for Drug Evaluation and Research.

  5. U.S. Food and Drug Administration. Assessment of Pressor Effects of Drugs. Draft Guidance for Industry. 2022.

  6. U.S. Food and Drug Administration. Division of Pharmacometrics: Selected Guidance and Resources on Exposure-Response and Concentration-QT Analysis. Center for Drug Evaluation and Research.

  7. U.S. Food and Drug Administration. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. Guidance for Industry. 2005.

  8. U.S. Food and Drug Administration. QTc Information in Human Prescription Drug and Biological Product Labeling. Guidance for Industry. December 2025.

  9. International Council for Harmonisation. S7A Safety Pharmacology Studies for Human Pharmaceuticals. 2001.

  10. U.S. Food and Drug Administration. Drug-Induced Cardiotoxicity Rank (DICTrank) Dataset. Center for Drug Evaluation and Research.

Revision History

Related Articles

Drug-Induced QT Prolongation: Cardiac Safety Assessment in Clinical Development and Pharmacovigilance

Understand how drug-induced QT prolongation is identified and evaluated, why QTc prolongation is an imperfect marker of proarrhythmic risk, how E14 and S7B integrate clinical and nonclinical evidence, and how safety physicians assess cardiac safety during development and after approval.

Drug-Induced Hematologic Toxicity: Hematologic Safety Assessment in Clinical Development and Pharmacovigilance

Understand how drug-induced hematologic toxicity is recognised and medically evaluated, how cytopenias are characterised by lineage, severity and mechanism, and how hematologic safety signals are assessed across clinical development and pharmacovigilance.

Drug-Induced Kidney Injury: Renal Safety Assessment in Clinical Development and Pharmacovigilance

Understand how drug-induced kidney injury is identified and medically evaluated, why kidney function and kidney injury are not the same, how renal biomarkers support clinical-trial safety assessment, and how pharmacovigilance teams evaluate potential nephrotoxicity.